Upstream Bio, Inc. (UPB) stock
UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.00−0.08 (-3.85%)
Close on Nov 19, 2026Market cap $109.54MP/E –Yield –
Upstream Bio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Upstream Bio's free cash flow for the twelve months ending Dec 31, 2025 was -$133.44M. For fiscal 2025 it was -$133.44M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$133.44M | – |
| FY2024 | Dec 31, 2024 | -$59.68M | – |
| FY2023 | Dec 31, 2023 | -$38.07M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$54.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.69M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.30M | – |
| Q4 FY2024 | Dec 31, 2024 | -$19.80M | – |
| Q4 FY2023 | Dec 31, 2023 | -$16.11M | – |
See a number that looks wrong?